What is the difference between Tirzepatide and Semaglutide?

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist, adding the GIP receptor pathway on top of GLP-1. The second pathway supports insulin sensitivity and energy balance alongside the appetite regulation both compounds share.

Is Tirzepatide stronger than Semaglutide?

In head-to-head clinical research, the dual GLP-1/GIP mechanism of Tirzepatide has produced more pronounced metabolic effects than single-agonist Semaglutide. For broader mechanistic coverage still, the triple agonist Retatrutide adds glucagon receptor activation on top of both.

Can I buy Tirzepatide in Canada?

Yes. Vancouver Island Peptides supplies Tirzepatide as a research compound synthesized in Vancouver, BC, available in 10mg and 20mg vials. It ships Canada-wide in discreet packaging and is sold for research and personal wellness purposes only, not approved by Health Canada for human use.

Which should I research first?

Semaglutide has the deepest evidence base and is the standard comparator. Tirzepatide offers a second mechanism with a substantial clinical record of its own. The choice depends on whether the research question concerns the GLP-1 pathway alone or the combined GLP-1/GIP response.

← Vancouver Island Peptides / Blog

GLP-1 Research Peptides — Comparison

Tirzepatide vs Semaglutide: Dual vs Single Agonist

July 18, 2026

Semaglutide and Tirzepatide are the two most widely researched GLP-1 compounds available to Canadian researchers. They are closely related but not equivalent — the difference is one additional receptor pathway, and it changes the metabolic profile meaningfully.

One receptor, or two

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP agonist — it keeps everything Semaglutide does and adds a second pathway.

Compound	Receptor Targets	Generation
Semaglutide	GLP-1	First — single agonist
Tirzepatide	GLP-1 + GIP	Second — dual agonist
Retatrutide	GLP-1 + GIP + Glucagon	Third — triple agonist

The two pathways Tirzepatide engages:

GLP-1 — appetite regulation, gastric emptying, insulin response (the pathway Semaglutide uses)
GIP — supports insulin sensitivity and energy balance, the mechanism Semaglutide lacks

What the research shows

In head-to-head clinical research, Tirzepatide's dual mechanism has produced more pronounced metabolic effects than single-agonist Semaglutide. That said, Semaglutide remains the more extensively studied of the two and the standard comparator for the entire compound class — depth of evidence is its genuine advantage.

Where Retatrutide fits

One generation further on. Retatrutide is a triple agonist, adding glucagon receptor activation — which increases energy expenditure — on top of the GLP-1 and GIP pathways Tirzepatide covers. See our Retatrutide vs Semaglutide comparison for that pairing.

Sourcing in Canada

Vancouver Island Peptides supplies both as domestic research compounds — synthesized at our Vancouver, BC lab partner, HPLC-verified to >99% purity, shipped Canada-wide in discreet packaging. Tirzepatide is available in 10mg and 20mg vials, Semaglutide in 30mg. Nothing crosses a border, so there is no customs seizure risk and no cold-chain uncertainty.

View Tirzepatide Canada View Semaglutide Canada

All products are intended for research and personal wellness purposes only. Not for human consumption. Not approved by Health Canada. Consult a qualified healthcare provider before use. Ships within Canada only.